摘要
目的:探讨曲美布汀对肠易激综合征(IBS)患者白细胞介素(IL)-18、IL-10和肿瘤坏死因子(TNF)-α水平的影响及疗效观察。方法:68例1BS患者。随机分为观察组和对照组。两组患者均予以胃肠解痉药、止泻药及维持水电解质和酸碱平衡等常规治疗。观察组在此基础上加用曲美布汀片200 mg,po,tid,疗程4周。比较两组患者治疗前后血清IL-18、IL-10和TNF-α水平变化,观察两组临床疗效和药物不良反应。结果:治疗4周后,两组患者血清IL-18、TNF-α较前明显下降,IL-10水平较前明显升高(P<0.05或0.01);且观察组下降或升高幅度较对照组更明显(P<0.05)。观察组临床总有效率明显高于时照组(P<0.05)。观察组和对照组分别发生药物不良反应3例、5例,均较轻微。结论:曲美布汀治疗1BS疗效显著,安全性较佳。其作用机制可能与降低血清IL-18、TNF-α水平。升高血清IL-10的水平,抑制机体的炎症反应有关。
Objective： To discuss the influence and curative effect of trimebutine on the levels of intedeukin-18 （IL-18） and 10 （IL-10） and tumor necrnsis factor-or （TNF-ot） in the patients with ilTitable bowel syndrome （IBS）. Methods： Totally 68 cases with IBS were selected and divided into the observation group and the control group randomly. The patients were given routine medical treat- ment, including administration of gastrointestinal antispasmodic drugs （50mg per time, rid） and antidiarrheal agent drugs （ compound diphenoxylate, 2.5-5.0rag per time, 2-4 times a day）, and maintaining the water-electrolyte and acid-base balance. The patients in the observation group were additionally given trimebutine tablets orally for 4-week treatment course. The changes in serum IL-18, IL-10 and TNF-α levels in the two groups before and after the medical treatment were compared, and the clinical curative effect and drug ad- verse reactions were observed as well. Results： After the 4-week medical treatment, the serum IL-18 and TNF-α levels were obviously declined in both groups （P 〈0.05 or P 〈0.01 ）, while IL-10 level was obviously increased. The decrease and increase rate in the ob- seivation group were much higher than those in the control group （ P 〈 0.05）. Meanwhile, the total clinical efficiency in the observa- tinn group was much higher than that in the control grnup （ P 〈 0.05 ）. No obvious drug adverse reaction appeared in both groups dur- ing the medical treatment. Conclusion： Trimebntine has reliable curative effect on IBS with high safety, and the mechanism may be rel- ative to the effects of reducing serum IL-18 and TNF-α levels, rising serum IL-10 level and inhibiting the inflammatory reaction.
出处
《中国药师》
CAS
2014年第1期108-110,共3页
China Pharmacist
